Doctors are seeing an increasing number of cases where the use of GLP-1 drugs (GLP-1 receptor agonists) turns into eating disorders, sometimes referred to as "agonorexia"[1]. According to available data from extensive medical records, the cumulative incidence of new diagnoses of eating disorders (mainly anorexia nervosa) was 1.275%, with patients with pre-existing mental disorders having more than twice the risk[1]. Some estimates suggest that up to one-third (35%) of new eating disorder diagnoses may come from people taking GLP-1 agonists[1]. Among users of these drugs, eating disorders occur, including feelings of guilt after eating (24.1%), fear of gaining weight (37.9%), and episodes of binge eating (6.9%)[3]. Doctors often have little training in eating disorders and often fail to recognize them in overweight patients[1]. Experts emphasize the need for routine psychological examinations and a multidisciplinary approach involving endocrinologists, psychologists and nutritionists in the treatment of patients using GLP-1 drugs[3].